blog

Gut Fungi and IBD: A Small Study Broadens the Microbiome Picture

A small IBD study linked fluconazole with gut fungal and bacterial changes. Learn what the findings mean and why they do not justify self-treatment.

Gut Fungi and IBD: A Small Study Broadens the Microbiome Picture
Share
PinterestFacebookLinkedInWhite Reddit alien mascot face icon on transparent background.White paper airplane icon on transparent background.White stylized X logo on black background, representing the brand X/Twitter.
Oct 27, 2026
Gut Microbiome

On September 1, 2026, Nature Medicine published online a Weill Cornell Medicine study linking fluconazole with lower intestinal fungal burden and improved disease activity in people with inflammatory bowel disease (IBD) and oral thrush. NewYork-Presbyterian's account of the IVAN study also described changes in the gut microbial community.

What was the earlier focus of IBD microbiome research?

Before IVAN, gut-microbiome research in IBD had placed greater emphasis on bacteria. Ellen Scherl, a study coauthor and IBD specialist at NewYork-Presbyterian and Weill Cornell Medicine, described that history in the hospital's account of the findings. She said fungi may contribute to inflammation in some patients.

That is the relevant background rather than a claim that medicine had already settled the role of every microbial group. The study enters a field whose attention has been unevenly distributed. Its central contribution is to ask whether the fungal part of the community deserves more attention alongside bacteria.

The term mycobiome means the fungal part of the gut microbial community. It helps distinguish fungi from the broader microbiome without treating them as a separate digestive system. For readers used to hearing mainly about bacteria, a wider view of gut microbes provides context for this change in focus.

The scientific question also shifts with that wider view. Instead of asking only which bacteria are present, researchers can ask how changes in fungi relate to bacterial communities and the substances microbes produce. IVAN brought those questions into a defined clinical setting.

What did the IVAN study find about gut fungi?

IVAN stands for IBD Therapy Via Antifungal-driven Microbiota Normalization. According to NewYork-Presbyterian, researchers included 53 people with mild-to-moderate Crohn’s disease or ulcerative colitis. All also had oral thrush associated with Candida overgrowth.

Over eight weeks, the study compared fluconazole with nystatin, an oral antifungal wash. Fluconazole was associated with lower intestinal fungal burden, meaning less fungus was detected in the gut. The report also described changes in gut microbial composition and improved clinical disease activity in that group.

Those findings connect measurements at several levels. The researchers considered fungal burden alongside bacterial community patterns and clinical activity. The resulting picture is broader than simply whether a mouth infection cleared.

Why was the comparison between treatments informative?

Both treatments resolved oral thrush, according to the hospital's report. Yet the same intestinal and microbiome benefits reported with fluconazole were not reported with nystatin.

In an interview with HCPLive, senior author Iliyan Iliev explained the difference by site. He said fluconazole reduced Candida in the mouth and intestine. Nystatin cleared oral thrush without reducing gut Candida.

This makes the comparison informative for understanding the research question. An improvement at the oral site and a change in the intestinal community are distinct observations. The study examined both rather than treating the disappearance of thrush as the only outcome.

Why do bacterial changes matter in a fungal study?

NewYork-Presbyterian described several changes in the fluconazole group:

  • Greater bacterial diversity.
  • Recovery of bacteria the researchers described as beneficial.
  • Increased production of butyrate and other microbiome-derived metabolites.
  • Changes in microbial network structure.

Bacterial diversity refers to the variety of bacteria in the community. Metabolites are substances produced through microbial activity. Butyrate was one of the metabolites highlighted in this study.

The network finding concerns patterns of relationships across the microbial community. Together, these measurements direct attention toward the gut as an interacting system rather than a set of isolated organisms.

Iliev told HCPLive that targeting fungal overgrowth was followed by changes across the broader microbial community. That sequence is the main biological idea drawing attention here: a fungal target may be relevant to more than the fungi themselves. It creates a research question about interactions between microbial groups.

What does disease activity add to the picture?

The report's mention of improved clinical disease activity is important because it moves the discussion beyond microbial measurements alone. A study could describe a changed microbial community without addressing how active a person's disease was. IVAN's account included both the microbiome observations and the clinical observations.

These are still different kinds of outcomes. Lower fungal burden describes fungi at the intestinal site. A change in bacterial diversity describes another part of the community. Disease activity concerns the clinical condition being studied.

Keeping those outcomes separate makes the finding easier to read. The headline is not just that the antifungal was associated with fewer fungi. It is that the study reported a pattern across fungi and bacteria alongside improved clinical activity in the same selected population.

What are the study's main limitations?

The researchers described IVAN as a prospective observational study. Prospective means participants were followed forward in time. Its observational design does not establish that fluconazole caused the clinical or microbial changes. The findings are associations rather than proof of treatment efficacy.

Fluconazole was compared with another antifungal approach rather than with a placebo. This creates a specific comparison: the two treatments were associated with different intestinal findings even though both cleared oral thrush. It is not the same question as whether fluconazole improves IBD outcomes compared with a placebo. Keeping that distinction in view helps explain why the authors identified a placebo-controlled study as a next step.

Selection is another important boundary. Participants had mild-to-moderate IBD plus oral thrush associated with Candida overgrowth. The results do not establish benefit for people without IBD or for those with IBD but no oral thrush. They also do not turn bloating or irregularity into evidence of fungal overgrowth.

The study's size and duration also limit the questions it can answer. It involved a small clinical group over eight weeks. In his HCPLive interview, Iliev called for longer follow-up and endoscopic outcomes.

Longer follow-up would help assess whether changes persist beyond the observation period. Endoscopic outcomes involve examining the digestive tract from inside. They would add another way to evaluate the disease alongside the clinical activity described in the report.

Another constraint concerns the detail available to readers. The NewYork-Presbyterian account does not give numerical disease-activity score changes or response and remission rates. It also does not report effect sizes, confidence intervals or p-values. Without those details, the magnitude and statistical uncertainty of the reported changes cannot be assessed from the account.

Words such as “improved” describe a direction of change. They do not tell readers how large the difference was or how many people experienced it. That distinction matters when deciding how much weight a headline should carry.

Safety reporting needs the same precision. Both treatments were described as well tolerated, but the account does not provide numerical adverse-event rates or detailed safety results. That description should not be read as a general safety assurance for antifungal use.

These boundaries also qualify Iliev's interpretation that disease-associated fungi may play a role in IBD in some patients. That is different from establishing Candida as a general cause of IBD. It is also different from recommending routine antifungal treatment.

For an individual with IBD, medication questions belong with a qualified clinician who can assess that person's situation. The study is not a basis for self-diagnosing “gut Candida” or taking antifungals for everyday digestive complaints.

What should this mean for everyday food choices?

The next useful step is stronger clinical testing rather than broader wellness claims. The IVAN researchers identified larger, multicenter, placebo-controlled studies as the way to test outcomes in carefully selected patients with fungal dysbiosis, meaning an altered fungal community. That work would help determine whether the pattern seen here translates into a reliable clinical benefit.

For daily dietary choices, the distinction is straightforward: this was a comparison of antifungal treatments rather than an eating-pattern study. Its results provide no tested reason to remove foods or adopt a restrictive diet to reproduce the reported microbiome changes. Putting food-related digestive claims in context helps keep that distinction visible.

The realistic takeaway is a wider scientific view of the gut, not a new rule for the dinner plate. Fungi belong in the research conversation alongside bacteria. Dietary advice should remain tied to dietary evidence and a person's clinical needs rather than a medication headline.

How DigestGenius helps

A possible fungal role in IBD brings a familiar difficulty into sharper focus: deciding when an intriguing microbiome result is ready to inform health choices. DigestGenius uses its free educational articles and in-depth resources to explain the evidence behind digestive-health headlines, giving adults a clearer way to judge promising results alongside knowledge supported by stronger research.

Explore the Blog

Sources

  1. Targeting gut fungi may offer a new treatment pathway for ibd symptoms
  2. Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.

FacebookInstagramYouTubeXPinterest

Continue reading

New IBS Fiber Guide Puts Serving Sizes in Context
November 22, 2026
Food, Fiber & Nutrition

New IBS Fiber Guide Puts Serving Sizes in Context

read article
Why do bloating and constipation often happen together?
November 22, 2026
Bloating & Regularity

Why do bloating and constipation often happen together?

read article
How 24-Hour Body Clocks and Stress Patterns Drive Changes in Colon Activity and Microbes
November 21, 2026
Gut-Brain & Lifestyle

How 24-Hour Body Clocks and Stress Patterns Drive Changes in Colon Activity and Microbes

read article
understand your gut

Keep learning what supports a healthier gut

Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.

read the blog
Woman holding a colorful plant-rich bowl in a bright kitchen